CanSino Biologics Inc.
CASBFOTCHealthcare● Active
$3.97
+$0.97(+32.33%)
Market Cap$1.4B
P/E Ratio—
52W High$6.99
52W Low$3
CanSino Biologics Inc. (CASBF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CASBF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.03B | $0.82B | $0.35B | $1.03B | $4.30B |
| Cost of Revenue | $0.35B | $0.24B | $1.22B | $1.22B | $1.30B |
| Gross Profit | $0.68B | $0.58B | ($0.88B) | ($0.19B) | $3.00B |
| Gross Margin %(computed) | 66.07% | 70.37% | -253.78% | -18.10% | 69.85% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.42B | $0.64B | $0.78B | $0.88B |
| G&A Expenses | $0.00B | $0.19B | $0.29B | $0.28B | $0.23B |
| Total Operating Expenses | $0.80B | $0.98B | $1.16B | $1.18B | $1.20B |
| Operating Income | ($0.11B) | ($0.40B) | ($2.04B) | ($1.37B) | $1.94B |
| Operating Margin %(computed) | -10.96% | -48.90% | -589.60% | -132.75% | 45.14% |
| Interest Income | $0.07B | $0.06B | $0.10B | $0.07B | $0.08B |
| Interest Expense | $0.06B | $0.06B | $0.06B | $0.04B | $0.02B |
| Income Before Tax | $0.02B | ($0.38B) | ($1.98B) | ($1.18B) | $1.94B |
| Income Tax Expense | ($0.01B) | $0.00B | ($0.01B) | ($0.22B) | $0.03B |
| Net Income | $0.03B | ($0.38B) | ($1.48B) | ($0.91B) | $1.91B |
| Net Margin %(computed) | 2.63% | -45.93% | -429.55% | -88.21% | 44.52% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.11 | $-1.53 | $-6.01 | $-3.69 | $7.74 |
| Wtd Avg Shares | 0.25B | 0.25B | 0.25B | 0.25B | 0.25B |
| EBITDA | $0.06B | ($0.11B) | ($1.65B) | ($1.32B) | $1.85B |
| EBITDA Margin %(computed) | 5.91% | -13.32% | -476.76% | -127.91% | 43.01% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CNY · B
Explore more CanSino Biologics Inc. data
About CanSino Biologics Inc. (CASBF) Income Statement
CanSino Biologics Inc. (CASBF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CASBF reported revenue of $1.03B, gross profit of $0.68B (gross margin 66.07%), and net income of $0.03B — a net profit margin of 2.63%.
Frequently asked questions
CASBF · 4 questionsCanSino Biologics Inc. (CASBF) reported revenue of $1.03B for 2025, up 25.1% year-over-year.
CASBF revenueCASBF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08